Assessing the current state of opioid-dependence treatment across Europe: Methodology of the European quality audit of opioid treatment (EQUATOR) project

Heroin Addiction and Related Clinical Problems

Volumn 14, Issue 3, 2012, Pages 5-70

  Fischer, Gabriele ^a   Stöver, Heino ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b FRANKFURT UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Europe; Methodology; Opioid dependence; Survey; Treatment

Indexed keywords

ADULT; ARTICLE; DRUG MISUSE; DRUG USE; EMPLOYMENT STATUS; EUROPE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL PRACTICE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PRISON; QUESTIONNAIRE; SAMPLE SIZE;

EID: 84866558245     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. BACHA J., REAST S., PEARLSTONE A. (2010): Treatment practice and perceived challenges for European physicians treating opioid dependence. Heroin Addict Relat Clin Probl 12: 9-19.
2. BELL J., ZADOR D. (2000): A risk-benefit analysis of methadone maintenance treatment. Drug Saf 22: 179-190.
3. BRESLIN K.T., MALONE S. (2006): Maintaining the viability and safety of the methadone maintenance treatment program. J Psychoactive Drugs 38: 157-160.
4. DORAN C., HOLMES J., LADEWIG D., LING W. (2005): Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Addict Relat Clin Probl 7: 7-18.
5. EMCDDA. Harm reduction: evidence, impacts and challenges. Available at www.emcdda.europa.eu. Accessed on 29 March 2012.
6. FOUNTAIN J., STRANG J., GOSSOP M., FARRELL M., GRIFFITHS P. (2000): Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 95: 393-406.
7. GOSSOP M., MARSDEN J., STEWART D. NTORS after five years (National Treatment Outcome Research Study): changes in substance use, health and criminal behaviour in the five years after intake. Department of Health research report. Available at www.dh.gov.uk. Accessed on 31 January 2012.
8. HM GOVERNMENT. Drug strategy 2010: reducing demand, restricting supply, building recovery: supporting people to live a drug free life. Available at www.homeoffice.gov.uk. Accessed on 15 March 2012.
9. KAKINAMI L., CONNER K.R. (2010): Sampling strategies for addiction research. In P. G. Miller, J. Strang, P. M. Miller, Eds: Addiction Research Methods. Blackwell Publishing Ltd, Chichester, UK. pp. 27-42.
10. LEONARDI C., HANNA N., LAURENZI P., FAGETTI R. (2008): Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. Drug Alcohol Depend 94: 125-132.
11. LINTZERIS N., CLARK N., WINSTOCK A., DUNLOP A., MUHLEISEN P., GOWING L., ALI R., RITTER A., BELL J., QUIGLEY A., MATTICK R.P., MONHEIT B., WHITE J. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence. Available at www.health.gov.au. Accessed on 14 February 2011.
12. MANCIA G., LAURENT S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulfield M.J., Cifkova R., Clément D., Coca A., Dominiczak A., Erdine S., Fagard R., Farsang C., Grassi G., Haller H., Heagerty A., Kjeldsen S.E., Kiowski W., Mallion J.M., Manolis A., Narkiewicz K., Nilsson P., Olsen M.H., Rahn K.H., Redon J., Rodicio J., Ruilope L., Schmieder R.E., Struijker-Boudier H.A., Van Zwieten P.A., Viigimaa M., Zanchetti A. (2009): Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121-2158.
13. MAREMMANI I., NARDINI R., ZOLESI O., CASTROGIOVANNI P. (1994): Methadone dosages and therapeutic compliance during a methadone maintenance program. Drug Alcohol Depend 34: 163-166.
14. MAREMMANI I., PANI P.P., MELLINI A., Pacini M, Marini G, Lovrecic M, Perugi G, Shinderman M (2007): Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. J Addict Dis 26: 61-70.
15. MATTICK R.P., BREEN C., KIMBER J., DAVOLI M. (2009): Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev: CD002209.
16. MATTICK R.P., KIMBER J., BREEN C., DAVOLI M. (2008): Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev: CD002207.
17. McCance-Katz E.F., SULLIVAN L.E., NALLANI S. (2010): Drug Interactions of Clinical Importance among the Opioids, Methadone and Buprenorphine, and Other Frequently Prescribed Medications: A Review. Am J Addict 19: 4-16.
18. MEIERKORD H., BOON P., ENGELSEN B., Göcke K, Shorvon S, Tinuper P, Holtkamp M; European Federation of Neurological Societies (2010): EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 17: 348-355.
19. NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Methadone and buprenorphine for the management of opioid dependence. Available at www.nice.org.uk. Accessed on 19 April 2012.
20. NEWELL R., BURNARD P. (2011): Issues in Qualitative Data Collection. Research for Evidence-Based Practice in Healthcare. Wiley-Blackwell, Chichester, West Sussex, UK. pp. 71-89.
21. NHS EVIDENCE CLINICAL KNOWLEDGE SUMMARIES. Opioid dependence - Management. How should I start maintenance treatment with buprenorphine? Available at www.cks.nhs.uk. Accessed on 4 April 2012.
22. RADCLIFFE P., STEVENS A. (2008): Are drug treatment services only for 'thieving junkie scumbags'? Drug users and the management of stigmatised identities. Soc Sci Med 67: 1065-1073.
23. RONCERO C., FUSTE G., BARRAL C., Rodríguez-Cintas L., Martínez-Luna N., Eiroa-Orosa F.J., Casas M., on behalf of the PROTEUS study investigators (2011): Therapeutic management and comorbidities in opiate dependent patients undergoing a replacement therapy programme in Spain: the PROTEUS study. Heroin Addict Relat Clin Probl 13: 5-16.
24. SCOTTISH GOVERNMENT. The Road to Recovery: A New Approach to Tackling Scotland's Drug Problem. Available at www.scotland.gov.uk. Accessed on 7 June 2012.
25. STÖVER H. (2011): Barriers to Opioid Substitution Treatment Access, Entry and Retention: A Survey of Opioid Users, Patients in Treatment, and Treating and Non-Treating Physicians. Eur Addict Res 17: 44-54.
26. Vidal-Trecan G., VARESCON I., NABET N., BOISSONNAS A. (2003): Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 69: 175-181.
27. WELSH ASSEMBLY GOVERNMENT. Working Together to Reduce Harm: The Substance Misuse Strategy for Wales 2008-2018. Available at www.wales.gov.uk. Accessed on 7 June 2012.
28. WORLD HEALTH ORGANIZATION. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Available at www.who.int. Accessed on 28 May 2010.
29. WINSTOCK A.R., LEA T., JACKSON A.P. (2009): Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics. J Addict Dis 28: 57-63.
30. WINSTOCK A.R., LEA T., SHERIDAN J. (2009): What is diversion of supervised buprenorphine and how common is it? J Addict Dis 28: 269-278.
31. WITTCHEN H.U., APELT S.M., SOYKA M., Gastpar M, Backmund M, Gölz J, Kraus MR, Tretter F, Schäfer M, Siegert J, Scherbaum N, Rehm J, Bühringer G. (2008): Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 95: 245-257.
32. WITTCHEN H.U., BÜHRINGER G., REHM J. (2011): Ergebnisse und Schlussfolgerungen der PREMOS-Studie (Predictors, Moderators and Outcome of Substitution Treatment). Suchtmedizin in Forschung und Praxis 13: 199-299.
33. ZALLER N.D., BAZAZI A.R., VELAZQUEZ L., RICH J.D. (2009): Attitudes toward methadone among out-oftreatment minority injection drug users: implications for health disparities. Int J Environ Res Public Health 6: 787-797.